AnatomyOrganismsChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation Science
TYK2 KinasePhosphatidylinositol 3-KinasesMAP Kinase Signaling SystemProtein KinasesProtein-Serine-Threonine KinasesProtein Kinase InhibitorsCalcium-Calmodulin-Dependent Protein Kinasessrc-Family KinasesProtein-Tyrosine KinasesProtein Kinase Cp38 Mitogen-Activated Protein KinasesCyclic AMP-Dependent Protein KinasesMitogen-Activated Protein Kinase 1p21-Activated KinasesMitogen-Activated Protein Kinase KinasesJNK Mitogen-Activated Protein KinasesMitogen-Activated Protein Kinase 3PhosphorylationCreatine KinaseCDC2 Protein KinaseCyclin-Dependent KinasesMAP Kinase Kinase KinasesJanus Kinase 1eIF-2 KinaseCasein Kinase IICasein KinasesSignal TransductionPyruvate KinaseRibosomal Protein S6 KinasesJanus Kinase 2MAP Kinase Kinase 1Receptor Protein-Tyrosine KinasesThymidine KinaseExtracellular Signal-Regulated MAP KinasesMAP Kinase Kinase 41-Phosphatidylinositol 4-KinasePhosphotransferases (Alcohol Group Acceptor)Mitogen-Activated Protein KinasesCDC2-CDC28 KinasesProto-Oncogene ProteinsI-kappa B KinaseGlycogen Synthase Kinase 3Aurora Kinasesrho-Associated KinasesIsoenzymesProtein Kinase C-deltaProtein Kinase C-alphaTyrosineTransfectionReceptor, Interferon alpha-betaEnzyme ActivationMutationDiacylglycerol KinaseProtein BindingAMP-Activated Protein KinasesKineticsMolecular Sequence DataProto-Oncogene Proteins c-aktFocal Adhesion Kinase 1Cell LineMyosin-Light-Chain KinaseProteinsPhosphoproteinsFocal Adhesion Protein-Tyrosine KinasesBlotting, WesternRibosomal Protein S6 Kinases, 90-kDaBase SequenceIntracellular Signaling Peptides and ProteinsProtein Kinase C-epsilonMAP Kinase Kinase Kinase 1Amino Acid SequenceSubstrate SpecificityCalcium-Calmodulin-Dependent Protein Kinase Type 2Recombinant ProteinsProtein Kinase C betaRecombinant Fusion ProteinsCell Line, TumorTetradecanoylphorbol AcetateMAP Kinase Kinase 2ApoptosisCyclin-Dependent Kinase 2SerineCells, CulturedCyclic GMP-Dependent Protein KinasesAndrostadienesTumor Cells, CulturedJanus Kinase 3DNA-Binding ProteinsTOR Serine-Threonine KinasesBinding SitesCyclin-Dependent Kinase 5ImmunoblottingPhosphoglycerate KinaseProtein Structure, TertiaryChromonesPhosphorylase KinasePhosphotyrosineArginine KinaseRNA, MessengerCell Cycle Proteins
INHIBITORJanusInhibitorsJAK2InhibitionDEUCRAVACITINIBProteinPhosphorylationTarget tyrosineEnzymesMutationsPsoriasisDesigned to inhibitPseudokinase domainCytokinesCatalytic subunitEgfrBindsInhibitsActivator of transcriptionPhosphorylateTherapeuticPathwaysGeneConformationReceptorsFamilyChromosomalSimilarityDiseasesTopicalMutantDomains
INHIBITOR16
  • Sotyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor. (centerwatch.com)
  • OSAKA, JAPAN & CAMBRIDGE, MASS.--( Business Wire / Korea Newswire ) September 12, 2023 -- Takeda ( TSE:4502/NYSE:TAK ) today announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis. (koreanewswire.co.kr)
  • These Phase 2b results highlight the potential of TAK-279, a highly selective, oral TYK2 inhibitor, to improve clinical outcomes for people living with psoriatic arthritis," said Andy Plump, President R&D, Takeda. (koreanewswire.co.kr)
  • TAK-279 is a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor in late-stage development,[6] with approximately 1.3 million-fold greater selectivity for TYK2 as compared with JAK1. (koreanewswire.co.kr)
  • Takeda ( TSE:4502/NYSE:TAK ) today announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis. (cbinews.com)
  • Meanwhile, Bristol Myers Squibb is developing deucravacitinib, an oral treatment that the company says would be the first tyrosine kinase 2 (TYK2) inhibitor. (managedhealthcareexecutive.com)
  • Moreover, fewer participants taking the TYK2 inhibitor discontinued treatment due to adverse events than those taking placebo or Otezla. (managedhealthcareexecutive.com)
  • Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, has been approved by the US Food and Drug Administration (FDA) for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, the manufacturer announced on September 9. (medscape.com)
  • Cite this: FDA Approves Oral TYK2 Inhibitor Deucravacitinib for Treating Psoriasis - Medscape - Sep 12, 2022. (medscape.com)
  • Selective TYK2 Inhibition in Chronic Plaque Psoriasis This articles focuses on oral deucravacitinib, a first-in-class selective tyrosine kinase 2 inhibitor for the treatment of moderate-to-severe chronic plaque psoriasis. (medscape.com)
  • Inhibition of the Ras-MAPK pathway by expression of the dominant-negative Ras mutant HRasN17 or by addition of the MAPK kinase (MEK) inhibitor PD98059 reduced several of these parameters but failed to block transformation. (embl.de)
  • These new, positive, three-year results reinforce the long-term efficacy and well-established safety profile of once-daily Sotyktu, the first and only TYK2 inhibitor available, and add to our confidence in its role as an oral treatment of choice for adults with moderate-to-severe plaque psoriasis," April Armstrong, MD, MPH, POETYK PSO clinical investigator and chief of dermatology at UCLA, said in a statement. (consultantlive.com)
  • Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. (businessinsider.com)
  • This article compares deucravacitinib, a novel, selective TYK2 inhibitor, against apremilast, a PDE4 inhibitor and a widely used, relatively recent option for treating psoriasis. (psoriasiscouncil.org)
  • JAK1/JAK2 kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. (medscape.com)
  • Multiple tyrosine kinase inhibitor. (medscape.com)
Janus12
  • TYK2 is a member of the Janus kinase (JAK) family. (centerwatch.com)
  • Janus kinases function as pairs of homo- or heterodimers in the JAK-STAT pathways. (centerwatch.com)
  • Janus tyrosine kinases (JAKs), cytoplasmic tyrosine kinases that are non-covalently associated with the cytoplasmic tails of receptors for cytokines or polypeptidic hormones. (embl.de)
  • Binding of IL-10 to the extracellular domain of IL-10R1 activates phosphorylation of the receptor-associated Janus tyrosine kinases, JAK1 and Tyk2. (nih.gov)
  • As knowledge of their function increased and two more were discovered, a more serious name for them was substituted- Janus Kinase Inhibitors. (barfplaats.nl)
  • They knew that compounds that could block the action of JAKs (Janus Kinase Inhibitors or jakinhibs ) might have potential uses fighting abnormal immune-related processes in people - diseases like rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, leukemia and even aspects of CPOD. (barfplaats.nl)
  • Evolving Story of JAK Inhibitors for Treating Alopecia Areata Review the introduction of Janus kinase inhibitors and their application as the first-line therapeutic option for severe alopecia areata. (medscape.com)
  • Various cytokines and their receptors mediate intracellular signalling through pairs of Janus kinase family enzymes. (guidetopharmacology.org)
  • Macrophage polarization is mediated in part, through the canonical Janus- or TYK2-kinases (JAK)-Signaling signal transducers and activators of transcription (STAT) signaling pathway. (biorxiv.org)
  • Janus kinases (Jaks) are critical signaling elements for a large subset of cytokines. (openrheumatologyjournal.com)
  • In contrast, classical immune (type I/ II) cytokine receptors do not have intrinsic protein kinase activity but associate with the Janus family of kinases (JAKs). (openrheumatologyjournal.com)
  • Janus-associated kinases (JAKs) JAK1 and JAK2 mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. (medscape.com)
Inhibitors14
  • The catalytic subunits of protein kinases are highly conserved, and the structures of over 280 of the approximately 500 human kinase domains have been determined, leading to large screens to develop kinase-specific inhibitors for the treatments of a number of diseases. (wikipedia.org)
  • We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors. (rcsb.org)
  • X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochemical properties. (rcsb.org)
  • Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium. (managedhealthcareexecutive.com)
  • Three primary TKY2 inhibitors that are under investigation for potential use in psoriasis include deucravacitinib, an oral therapy that binds to the regulatory domain of TYK2, as well as brepocitinib and another drug known only as PF-06826647, which are two potent topical and oral TYK2 inhibitors, respectively. (medpagetoday.com)
  • Selective, allosteric inhibition of TYK2 signaling may reduce the potential for toxicities associated with other JAK inhibitors. (medpagetoday.com)
  • This article reviewed the efficacy and safety of JAK inhibitors in psoriasis to date, focusing specifically on TYK2 inhibitors. (medpagetoday.com)
  • Selective inhibition of TYK2 reduces the potential for AEs associated with JAK inhibitors (eg, hematologic and lipid abnormalities). (medpagetoday.com)
  • Also, not all TYK2 inhibitors are the same. (medpagetoday.com)
  • What does the foreseeable future hold for TYK2 inhibitors? (medpagetoday.com)
  • TYK2 inhibitors are efficacious against psoriasis. (medpagetoday.com)
  • These results highlight the interest of therapies targeting the PD-1/PD-L1 axis in activated lymphomas with PD-L1 expression, with possible synergies with tyrosine kinase inhibitors. (springer.com)
  • Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need. (skintherapyletter.com)
  • Unlike other JAK inhibitors, which target the active kinase domain, deucravacitinib targets the pseudokinase domain of TYK2, which gives it high selectivity and may also limit side effects and toxicity. (psoriasiscouncil.org)
JAK23
  • TYK2 pairs with JAK1 to mediate multiple cytokine pathways and also pairs with JAK2 to transmit signals as shown in cell-based assays. (centerwatch.com)
  • Now we're going after JAK1 and JAK2, and TYK2. (ajmc.com)
  • TYK2 dimerises with JAK2 to mediate IL-12 and IL-23 signalling (both are p40 subunit containing cytokines), and with JAK1 for the IFNα/β pathway. (guidetopharmacology.org)
Inhibition6
  • This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. (centerwatch.com)
  • The precise mechanism linking inhibition of TYK2 enzyme to therapeutic effectiveness in the treatment of adults with moderate-to-severe plaque psoriasis is not currently known. (centerwatch.com)
  • Our hypothesis is that high selectivity, as seen with TAK-279, can enable high levels of TYK2 inhibition, while potentially avoiding toxicities associated with JAK inhibition. (koreanewswire.co.kr)
  • TYK2 has not been successfully targeted as yet, but laboratory and clinical evidence suggest that allosteric inhibition of TYK2 may be a viable therapeutic approach in psoriasis. (medpagetoday.com)
  • Chemical inhibition and siRNA knockdown experiments demonstrated that STAT-3 activation is dependent on the activation of nonreceptor tyrosine-protein kinase 2 (TYK2) and epidermal growth factor receptor (EGFR) tyrosine kinases. (cdc.gov)
  • To address the possibility that activation of phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR/FRAP), represents one of these pathways, we have examined the effect of simultaneous inhibition of the Ras-MAPK and PI3K-mTOR pathways on transformation of CEF by v-Src. (embl.de)
DEUCRAVACITINIB4
  • By homing in on TYK2, deucravacitinib inhibits signaling of interleukin (IL)-23, IL-12 and type 1 interferons, which are heavily involved in plaque psoriasis pathology. (managedhealthcareexecutive.com)
  • Some like deucravacitinib specifically block TYK2 without blocking other JAKs, which is ideal, while other TYK2 blockers have cross reactivity against other JAKs, which can lead to unwanted side effects. (medpagetoday.com)
  • Deucravacitinib (an oral once-daily pill) is the TYK2 blocker that is farthest along in clinical development and will likely be approved by the FDA within the next year. (medpagetoday.com)
  • Deucravacitinib targets TYK2, which inhibits signaling of interleukin-23, interleukin-12, and type 1 interferons, key cytokines involved in the pathogenesis of multiple immune-mediated diseases, according to Bristol Myers Squibb (BMS). (medscape.com)
Protein17
  • The protein kinase domain is a structurally conserved protein domain containing the catalytic function of protein kinases. (wikipedia.org)
  • Protein kinases are a group of enzymes that move a phosphate group onto proteins, in a process called phosphorylation. (wikipedia.org)
  • Protein kinases possess a catalytic subunit which transfers the gamma phosphate from nucleoside triphosphates (almost always ATP) to the side chain of an amino acid in a protein, resulting in a conformational and/or dynamic changes affecting protein function. (wikipedia.org)
  • Protein kinase function has been evolutionarily conserved from Escherichia coli to Homo sapiens. (wikipedia.org)
  • Eukaryotic protein kinases are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common with both serine/threonine and tyrosine protein kinases. (wikipedia.org)
  • This KI-PM allele should express the mutated Tyk2 Y1074F, Y1075F protein. (taconic.com)
  • Dependent on the substrate they act upon they can be broadly classified into 3 categories: protein kinases, carbohydrate kinases and lipid kinases. (horizondiscovery.com)
  • Mitogen-activated protein kinases such as RAF kinases involved in the MAPK signaling pathways and cyclin dependent kinases (CDKs) involved in cell cycle regulation are prime examples of pathways implicated in cancers. (horizondiscovery.com)
  • Focal-adhesion kinases (FAKs), cytoplasmic protein tyrosine kinases involved in signalling through integrins. (embl.de)
  • The drug candidate acts by targeting non receptor tyrosine protein kinase (TYK2). (pharmaceutical-technology.com)
  • We provide the phylogenetic tree of 496 human protein kinases created by using our accurate structure-based multiple sequence alignment. (fccc.edu)
  • The following table provides the number of human protein kinases in each group. (fccc.edu)
  • Structurally-Validated Multiple Sequence Alignment of 497 Human Protein Kinase Domains. (fccc.edu)
  • Belongs to the protein kinase superfamily. (lu.se)
  • Tyr protein kinase family. (lu.se)
  • This protein has been shown to bind tyrosine kinase TYK2, and thus may mediate the signaling processes that lead to the activation of JAK1, STAT3 and STAT6 induced by IL13 and IL4. (thermofisher.com)
  • Using whole- transcriptome sequencing, we identified a chimeric fusion involving NPM1 (5q35) and TYK2 (19p13) that encodes an NPM1-TYK2 protein containing the oligomerization domain of NPM1 and an intact catalytic domain in TYK2. (bvsalud.org)
Phosphorylation2
  • Depending upon the receptor, IRS2 undergoes phosphorylation, either via Tyk2 following type I IFN binding, or via JAK1 and 3 following IL-4, -7 and -15 binding. (rndsystems.com)
  • Formation of the cytokine receptor / JAK signaling complex and activation of JAK kinases leads to the phosphorylation of receptor chains, which creates docking sites for STAT ( S ignal T ransducers and A ctivators of T ranscription) transcription factors. (openrheumatologyjournal.com)
Target tyrosine2
  • Drugs that target tyrosine kinase 2 (TYK2) were found to mediate inflammation in plaque psoriasis while lowering the risk of adverse events (AEs) often associated with this class of drugs, according to new findings published in the Journal of the American Academy of Dermatology . (medpagetoday.com)
  • The drug is an oral medication which is tailored to target tyrosine kinase 2 (TYK2) specifically, thereby obstructing the signaling of crucial cytokines, including interleukin(IL)-23, IL-12, and Type 1 interferons, known to play a major role in the development of several different immune-mediated disorders. (consultantlive.com)
Enzymes2
  • Kinases are a large family of enzymes with over 500 encoded in the human genome and all share a highly conserved kinase domain. (horizondiscovery.com)
  • The synthesis, chemical derivatization, and investigation of the inhibitory properties of novel cyclitol derivatives on the phosphatidylinositol 4-kinase enzymes PI4K55 and PI4K230 involved in the phosphatidylinositol cycle are reported. (embl.de)
Mutations3
  • We found that natural genetic mutations in TYK2 can protect individuals from developing psoriasis without leading to an increased risk of infection. (medpagetoday.com)
  • Has been able to overcome imatinib resistance resulting from BCR/ABL kinase domain mutations. (medscape.com)
  • Under the conditions of the assays, was able to overcome imatinib resistance resulting from BCR/ABL kinase mutations in 32 of 33 mutations tested. (medscape.com)
Psoriasis3
  • TYK2 is a great new target for treating psoriasis and mediates inflammation in plaque psoriasis. (medpagetoday.com)
  • TYK2 can be safely blocked in psoriasis and provides therapeutic benefit to patients. (medpagetoday.com)
  • TYK2 is involved in the transmembrane signaling of key psoriasis-associated cytokines, including IL-12, IL-23, and type I interferons. (psoriasiscouncil.org)
Designed to inhibit1
  • Specifically designed to inhibit tyrosine kinase activity of the bcr-abl kinase in Ph+ leukemic CML cell lines. (medscape.com)
Pseudokinase domain1
  • Displacement of the ATP that binds to the JH2 pseudokinase domain allosterically disrupts TYK2 catalytic activity, in a mechanism that appears to stablise the kinase in an auto-inhibitory conformation. (guidetopharmacology.org)
Cytokines1
  • Despite the roughly 60 type I/II cytokines discovered, there are only four members in the JAK kinase family. (openrheumatologyjournal.com)
Catalytic subunit1
  • A well-known example of a lipid kinase is phosphoinositide 3-kinase which is implicated in a number of cancers, mainly through alterations to its catalytic subunit - PIK3CA. (horizondiscovery.com)
Egfr2
  • Approximately 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M). (rcsb.org)
  • Our studies show that poultry dust extract controls the induction of immune and inflammatory mediator expression via a cellular pathway involving oxidative stress-mediated STAT-3 activation by TYK2 and EGFR tyrosine kinases. (cdc.gov)
Binds2
  • Sotyktu binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. (centerwatch.com)
  • The PX domain of Vam7p selectively binds PtdIns-3-P, while the PX domain of the CPK PI-3 kinase selectively binds PtdIns-4,5-P(2). (embl.de)
Inhibits1
Activator of transcription1
  • Functionally, NPM1-TYK2 induced constitutive TYK2, signal transducer and activator of transcription 1 (STAT1), STAT3, and STAT5 activation. (bvsalud.org)
Phosphorylate1
  • These kinases then phosphorylate specific tyrosine residues (Y446 and Y496) on the intracellular domain of the IL-10R1 chain. (nih.gov)
Therapeutic1
  • This is the first report of recurrent translocations involving TYK2, and it highlights the novel therapeutic opportunities in the treatment of CD30-positive LPDs with TYK2 translocations. (bvsalud.org)
Pathways1
  • Both of these TYK2-dependent pathways are validated as druggable targets for the development of pharmaceuticals for the treatment of autoimmune diseases. (guidetopharmacology.org)
Gene1
  • A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. (bvsalud.org)
Conformation1
  • Broadly, the state or conformation of the kinase may be classified as DFGin or DFGout, depending on whether the Asp residue of the DFG motif is in or out of the active site. (wikipedia.org)
Receptors2
  • Tyrosine kinase 2 (TYK2), a member of the JAK family of kinases, regulates signaling and functional responses downstream of the interleukin 12, interleukin 23, and type I interferon receptors. (medpagetoday.com)
  • Growth factor cytokine receptors typically have intrinsic kinase activity. (openrheumatologyjournal.com)
Family1
Chromosomal1
  • Chromosomal translocations targeting tyrosine kinases in CD30-positive LPDs have not been described. (bvsalud.org)
Similarity1
  • The table below shows human diseases predicted to be associated to Tyk2 by phenotypic similarity . (mousephenotype.org)
Diseases1
  • The table below shows human diseases associated to Tyk2 by orthology or direct annotation . (mousephenotype.org)
Topical1
  • More TYK2 blockers are in the pipeline, including topical TYK2. (medpagetoday.com)
Mutant1
  • Conversely, a kinase -defective NPM1-TYK2 mutant abrogated STAT1/3/5 signaling. (bvsalud.org)
Domains1
  • 1 kinase has 2 domains in the OTHER category (EIF2AK4) (484 + 6 + 2 + 4 + 1 = 497 domains). (fccc.edu)